Production (Stage)
Cytophage Technologies Ltd.
CYTO.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.81M | 3.25M | 3.45M | 3.41M | 3.55M |
| Depreciation & Amortization | 561.70K | 516.30K | 520.70K | 475.30K | 431.40K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.39M | 3.78M | 3.99M | 3.90M | 3.99M |
| Operating Income | -3.39M | -3.78M | -3.99M | -3.90M | -3.99M |
| Income Before Tax | -3.41M | -5.78M | -5.84M | -5.77M | -5.72M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.41 | -5.78 | -5.84 | -5.77 | -5.72 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.41M | -5.78M | -5.84M | -5.77M | -5.72M |
| EBIT | -3.39M | -3.78M | -3.99M | -3.90M | -3.99M |
| EBITDA | -3.03M | -3.42M | -3.65M | -3.57M | -3.64M |
| EPS Basic | -0.06 | -0.11 | -0.12 | -0.12 | -0.12 |
| Normalized Basic EPS | -0.04 | -0.04 | -0.05 | -0.05 | -0.05 |
| EPS Diluted | -0.06 | -0.12 | -0.12 | -0.12 | -0.13 |
| Normalized Diluted EPS | -0.04 | -0.04 | -0.05 | -0.05 | -0.05 |
| Average Basic Shares Outstanding | 215.47M | 211.32M | 200.19M | 189.02M | 177.54M |
| Average Diluted Shares Outstanding | 215.47M | 211.32M | 200.19M | 189.02M | 177.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |